AtriCure, Inc. reported a significant increase in financial performance for the second quarter of 2025, with total revenue reaching $136.1 million, a 17.1% increase from $116.3 million in the same period of 2024. For the first half of 2025, revenue totaled $259.8 million, up 15.4% from $225.1 million year-over-year. The company’s gross profit for the quarter was $101.5 million, yielding a gross margin of 74.5%, slightly down from 74.7% in the prior year. Despite the revenue growth, AtriCure recorded a net loss of $6.2 million for the quarter, an improvement from a loss of $8.0 million in Q2 2024.
The company’s operational expenses also increased, with research and development costs rising by 43.4% to $29.3 million, driven by clinical trial expenses and milestone payments related to acquired in-process research and development. Selling, general, and administrative expenses increased by 6.5% to $78.4 million, primarily due to higher personnel costs. The overall operating expenses for the quarter totaled $107.7 million, up from $94.0 million in the previous year. AtriCure's accumulated deficit as of June 30, 2025, stood at $414.7 million, compared to $401.8 million at the end of 2024.
Strategically, AtriCure has focused on product innovation and clinical research, with notable advancements including the FDA's 510(k) clearance for the AtriClip® PRO-Mini™ LAA Exclusion System and the cryoICE® cryoXT™ probe, both expected to launch in the second half of 2025. The company has also made strides in clinical trials, completing enrollment for the LeAAPS trial, which evaluates the effectiveness of LAA exclusion in preventing strokes. These initiatives are part of AtriCure's broader strategy to enhance product adoption and expand market share in the surgical treatments for atrial fibrillation and pain management.
In terms of operational metrics, AtriCure reported a total of 49,691 shares outstanding as of June 30, 2025, reflecting an increase from 48,869 shares at the end of 2024. The company continues to expand its geographic reach, selling products through direct sales and distributors in key markets including the United States, Europe, and Asia Pacific. The international revenue for the second quarter was $25.6 million, a 23.3% increase from the previous year, indicating strong growth across various regions.
Looking ahead, AtriCure anticipates continued revenue growth driven by its product launches and ongoing clinical studies. The company remains focused on enhancing its product offerings and expanding its market presence, despite facing increased competition in its key markets. AtriCure's management expressed optimism about the future, emphasizing the importance of innovation and physician education in driving adoption of its surgical solutions.
About AtriCure, Inc.
AtriCure, Inc. develops and markets medical devices for the surgical treatment of atrial fibrillation (Afib), left atrial appendage management (LAAM), and post-operative pain management. Its product portfolio includes radiofrequency and cryoablation systems, the AtriClip LAA exclusion device, and cryo nerve block probes. Serving cardiothoracic surgeons and electrophysiologists globally, AtriCure’s technologies offer clinically proven, less invasive solutions to improve patient outcomes and reduce stroke risk and post-surgical pain.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.